Skye Bioscience to acquire Redx Pharma; Redx holders to own ~46% of combined company

Skye Bioscience, Inc.

Skye to acquire Redx Pharma via UK scheme of arrangement; Redx valued at $125M, Skye at $14.5M.
Post-close ownership: Redx shareholders ~46.17%, Skye ~5.38%, new investors ~48.45% (assuming $67.9M concurrent financing).
Concurrent financing of $67.9M (up to $72.9M) plus $5M side letter and $22M equity line; warrant valued at $5M.
Redx management to lead combined company: Lisa Anson CEO, Peter Collum CFO; current Skye executives and board to resign.
Shareholders to receive CVRs: Skye legacy CVR (90% of net proceeds from certain assets) and Redx CVR (100% of Redx asset proceeds).

item 1.01 item 3.02 item 3.03 item 5.01 item 5.02 item 5.03 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Tu Diep

Other Named Officer

SKYE · Skye Bioscience, Inc.

Effective: 2027-01-31
Filed: August 14, 2026, 9:36 AM ET

Tu Diep has entered into a previously disclosed executive employment agreement (the “ Diep Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Diep (the “ Diep Separation Agreement ”) pursuant to which Mr. Diep's last day of employment with the Company will be January 31, 2027

Departed

Punit Dhillon

Other Named Officer

SKYE · Skye Bioscience, Inc.

Effective: 2027-08-31
Filed: August 14, 2026, 9:36 AM ET

Punit Dhillon has entered into a previously disclosed executive employment agreement (the “ Dhillon Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Dhillon (the “ Dhillon Separation Agreement ”) pursuant to which Mr. Dhillon's last day of employment with the Company will be August 31, 2027

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Tu Diep departed as other_named_officer at Skye Bioscience, Inc..

Action: separate

Exact text from the filing

Tu Diep has entered into a previously disclosed executive employment agreement (the “ Diep Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Diep (the “ Diep Separation Agreement ”) pursuant to which Mr. Diep's last day of employment with the Company will be January 31, 2027

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Punit Dhillon departed as other_named_officer at Skye Bioscience, Inc..

Action: separate

Exact text from the filing

Punit Dhillon has entered into a previously disclosed executive employment agreement (the “ Dhillon Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Dhillon (the “ Dhillon Separation Agreement ”) pursuant to which Mr. Dhillon's last day of employment with the Company will be August 31, 2027

View on SEC.gov

Skye Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-056966

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.